NCT05012371 2026-03-05
Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
Clinical Trials
30 trialsNCT01217931 2026-01-30
Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03173560 2025-04-01
Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma
Eisai Inc.
Phase 2 Completed
NCT06211790 2024-01-18
Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma
Fudan University
Phase 2 Recruiting
NCT00830895 2022-11-09
RAD001 for Non-clear Cell Renal Cell Carcinoma (RCC)
Seoul National University Hospital
Phase 2 Completed
NCT03163667 2022-09-15
ENTRATA
Calithera Biosciences, Inc
Phase 2 Completed
NCT01399918 2022-02-01
Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC)
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT05124431 2021-11-18
ALTER-UC-001
Fudan University
Phase 2 Unknown
NCT01185366 2021-04-28
Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00827359 2021-02-24
Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02187302 2020-05-28
CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)
Lumos Pharma
Phase 2 Completed
NCT01239342 2019-10-10
Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT01731158 2019-02-06
BERAT
Central European Society for Anticancer Drug Research
Phase 2 Completed
NCT02560012 2018-10-12
Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
The University of Texas Health Science Center, Houston
Phase 2 Terminated
NCT00529802 2018-04-25
Exploratory Study Evaluating Fluorodeoxyglucose - Position Emission Tomography as a Predictive Marker for Therapy With RAD001 in Metastatic Renal Cell Cancer
University of Chicago
Phase 2 Completed
NCT00331409 2017-10-26
Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer
OHSU Knight Cancer Institute
Phase 2 Completed
NCT01784978 2017-10-02
SUNRISES
Associació per a la Recerca Oncologica, Spain
Phase 2 Terminated
NCT00651482 2017-04-11
Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus)
Stanford University
Phase 2 Terminated
NCT00719264 2017-03-20
Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer
Novartis
Phase 2 Completed
NCT02273752 2017-02-03
Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer
Emory University
Phase 2 Terminated
NCT00903175 2016-11-08
RECORD-3
Novartis
Phase 2 Completed
NCT00688753 2016-09-02
MACS0460
Novartis
Phase 2 Completed
NCT01715935 2016-08-19
NEORAD
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
Phase 2 Completed
NCT01442090 2016-08-10
Study of GDC-0980 Versus Everolimus in Participants With Metastatic Renal Cell Carcinoma Who Have Progressed on or Following Vascular Endothelial Growth Factor- (VEGF) Targeted Therapy
Genentech, Inc.
Phase 2 Completed
NCT01491672 2016-06-06
RECORD-4
Novartis
Phase 2 Completed
NCT00831480 2016-03-21
Everolimus (RAD001) For Advanced Renal Cell Carcinoma (RCC) Before Kidney Removal
Baylor College of Medicine
Phase 2 Terminated
NCT00446368 2016-03-17
RAD001
The Methodist Hospital Research Institute
Phase 2 Completed
NCT01408004 2014-07-16
ROPETAR
Netherlands Working Group on Immunotherapy of Oncology
Phase 2 Completed
NCT01793636 2014-06-24
ZEBRA
Queen Mary University of London
Phase 2 Terminated
NCT01616186 2013-04-08
Everolimus/Sorafenib or Sunitinib in Patients With Metastatic Renal Cell Carcinoma (RCC)
University of California, San Francisco
Phase 2 Withdrawn